The Immunomodulatory Role of Galectin-1 in the Tumour Microenvironment and Strategies for Therapeutic Applications
Cancers,
Год журнала:
2025,
Номер
17(11), С. 1888 - 1888
Опубликована: Июнь 5, 2025
With
the
morbidity
of
cancer
currently
on
a
perpetual
rise,
there
is
critical
need
for
new
treatment
options.
Current
therapeutic
options,
such
as
chemotherapy
and
radiotherapy,
are
frequently
employed;
however,
high
rate
recurrence
underscores
incomplete
understanding
tumour
growth,
progression,
intricacies
their
microenvironments.
In
this
study,
we
review
roles
that
galectin-1
(Gal1)
plays
in
suppressing
immune
surveillance
microenvironment.
Studies
have
shown
Gal1
changes
system
parameters:
T
cell
function,
sensitising
resting
lymphocytes
to
Fas/FasL,
decreasing
proliferation,
reducing
adhesion
extracellular
matrix,
inhibiting
Th1
cytokines,
increasing
M2
phenotype
macrophages,
promoting
angiogenesis.
has
garnered
attention
potential
target
due
its
involvement
progression
evasion.
Given
limitations
toxic
side
effects
associated
with
current
alternative
strategies
targeting
been
explored
potential.
Approaches
OTX008,
anti-Gal1
monoclonal
antibodies,
Gal1-targeted
vaccines
demonstrated
ability
downregulate
by
activity.
These
findings
highlight
promise
not
only
novel
therapy
but
also
prognostic
biomarker,
offering
opportunities
development
more
effective
less
strategies.
Язык: Английский
Sugar mimics and their probable binding sites: design and synthesis of thiazole linked coumarin-piperazine hybrids as galectin-1 inhibitors
RSC Advances,
Год журнала:
2024,
Номер
14(49), С. 36794 - 36803
Опубликована: Янв. 1, 2024
Synthesis
of
Gal-1
inhibitors
with
binding
site
analysis
using
1.2
μs
MD
replicas
and
machine
learning.
Язык: Английский